$ARQT (Arcutis Biotherapeutics Inc) ๐๐ผ๐๐๐๐๐๐
๐๐ช๐ข๐ข๐๐ง๐ฎ
CEO Frank Watanabe reported strong sales and demand growth for the ZORYVE franchise, citing continued adoption among healthcare providers and patients. He highlighted the FDA approval of ZORYVE foam 0.3% for plaque psoriasis of the scalp and body the companyโs fifth FDA approval for ZORYVE in three years and reaffirmed the focus on converting topical steroid prescriptions to ZORYVE. Watanabe reiterated that the company is on track to reach cash flow breakeven in 2026 and announced the termination of ARQ-255 development following Phase Ib results.
Chief Commercial Officer Todd Edwards reported ZORYVE net product revenue of $81.5M, representing 164% year-over-year growth and 28% sequential growth. He expects continued growth from new indication launches, expanded PCP and pediatric channels through Kowa, and ongoing market share gains from steroid conversions, though he cautioned about seasonal moderation in Q3 before a stronger Q4 rebound.
CFO Latha Vairavan noted that operating leverage improvements reduced cash burn, resulting in positive operating cash flow of $325K for the quarter. The company ended with $191.1M in cash and securities and $108M in total debt, with access to an additional $100M through mid-2026.
๐๐๐ฃ๐๐๐๐๐ก๐จ:
Net product revenue: $81.5M (+28% QoQ, +164% YoY)
Cost of sales: $7.5M
R&D: $19.5M
SG&A: $69.2M (reflecting commercial investment)
Net loss: reduced by $36.4M YoY and $9.2M QoQ
๐๐ช๐ฉ๐ก๐ค๐ค๐ :
Management reaffirmed the goal of cash flow breakeven in 2026, supported by upcoming ZORYVE cream 0.05% approval for children (expected October 2025) and continued expansion in both dermatology and pediatric markets.
๐๐๐จ๐ ๐จ ๐๐ฃ๐ ๐พ๐ค๐ฃ๐๐๐ง๐ฃ๐จ:
Arcutis noted seasonal fluctuations typical of prescription topical products, expecting slower Q3 growth followed by a rebound. Management cited ongoing Medicare Part D access challenges due to complexities from the Inflation Reduction Act, noting that few, if any, new drugs have been added to formularies this year. The discontinuation of ARQ-255 underscores the companyโs data-driven capital discipline. Additional risks include dependence on external innovation and potential need for incremental capital for future acquisitions.
๐๐๐ฃ๐๐ก ๐๐๐ ๐๐๐ฌ๐๐ฎ:
Arcutis delivered strong sequential revenue growth and continued ZORYVE adoption, supported by new approvals and label expansions. Management reaffirmed its focus on reaching cash flow breakeven by 2026, emphasizing operating leverage, steroid-to-ZORYVE prescription conversion, and selective R&D investment. Despite reimbursement and seasonal headwinds, the company remains on a clear path toward sustained growth, profitability, and disciplined expansion.
๐๐ค๐ง๐ฉ๐๐ค๐ก๐๐ค ๐๐๐ง๐๐ค๐ง๐ข๐๐ฃ๐๐:
๐ฉ ๐๐๐ฟ ๐๐๐ฉ๐ช๐ง๐ฃ๐จ: 30,09% ๐๐ฐ
๐ฉ ๐ฎ-๐๐๐๐ง ๐๐๐ฉ๐ช๐ง๐ฃ๐จ: 104,52% ๐๐ฐ
โ ๏ธRisk level 5 โ ๏ธ
Thank you for your trust and remember stay green! ๐๐
www.etoro.com/people/madmanyuri
... Show More
We use our own and third-party cookies on our websites to enhance your experience, analyze traffic, and for security and marketing. For more info, see our Cookie Policy or go to Manage Settings.
Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information
Manage Consent Preferences
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Cookie List
label
ConsentLeg.Interest
label
label
label
Tue Jan 20 2026 05:56:32 GMT+0000 (Coordinated Universal Time)
